Product Description
Livzon Pharma is developing LZ001 tablets, a small molecule ROS1/NTRK/ALK multi-kinase Inhibitor.
Mechanisms of Action: ROS1 Inhibitor, ALK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Livzon Pharmaceutical
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20221852 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/20/2025 |
News Article |
CPSC Warns Consumers Immediately to Stop Using Uomeod Mini Steamers Due to Burn Hazard; Sold on Amazon.com |